Elicio Therapeutics (ELTX) has priced a registered direct offering of about 4.4 million common shares for gross proceeds of about $15 million, the company said Thursday.
The offering, led by two new fundamental institutional investors and an existing shareholder, is expected to close on or about July 6, Elicio said.
Net proceeds will be used to primarily fund the planned phase 1 clinical development of ELI-002 7P, as well as its pipeline and platform, working capital, and general corporate purposes, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments